Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. AU1993035723 - Use of muramyl peptide for the treatment of toxicity

Office Australie
Numéro de la demande 35723/93
Date de la demande 26.02.1993
Numéro de publication 1993035723
Date de publication 30.05.1996
Type de publication A
CIB
A61K 38/00
ANÉCESSITÉS COURANTES DE LA VIE
61SCIENCES MÉDICALE OU VÉTÉRINAIRE; HYGIÈNE
KPRÉPARATIONS À USAGE MÉDICAL, DENTAIRE OU POUR LA TOILETTE
38Préparations médicinales contenant des peptides
A61K 38/14
ANÉCESSITÉS COURANTES DE LA VIE
61SCIENCES MÉDICALE OU VÉTÉRINAIRE; HYGIÈNE
KPRÉPARATIONS À USAGE MÉDICAL, DENTAIRE OU POUR LA TOILETTE
38Préparations médicinales contenant des peptides
04Peptides ayant jusqu'à 20 amino-acides dans une séquence entièrement déterminée; Leurs dérivés
14Peptides contenant des radicaux saccharide; Leurs dérivés
A61P 39/02
ANÉCESSITÉS COURANTES DE LA VIE
61SCIENCES MÉDICALE OU VÉTÉRINAIRE; HYGIÈNE
PACTIVITÉ THÉRAPEUTIQUE SPÉCIFIQUE DE COMPOSÉS CHIMIQUES OU DE PRÉPARATIONS MÉDICINALES
39Agents protecteurs généraux ou antipoisons
02Antidotes
CPC
A61K 38/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
14Peptides containing saccharide radicals; Derivatives thereof ; , e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
A61P 39/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
39General protective or antinoxious agents
02Antidotes
Y10S 514/81
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
10TECHNICAL SUBJECTS COVERED BY FORMER USPC
STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
514Drug, bio-affecting and body treating compositions
81Addiction
Y10S 514/811
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
10TECHNICAL SUBJECTS COVERED BY FORMER USPC
STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
514Drug, bio-affecting and body treating compositions
81Addiction
811Alcohol
Y10S 514/812
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
10TECHNICAL SUBJECTS COVERED BY FORMER USPC
STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
514Drug, bio-affecting and body treating compositions
81Addiction
812Narcotic
Y10S 514/813
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
10TECHNICAL SUBJECTS COVERED BY FORMER USPC
STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
514Drug, bio-affecting and body treating compositions
81Addiction
813Tobacco
Déposants Peptech (UK) Limited
Mandataires FB Rice Pty Ltd
Données relatives à la priorité 9204354 28.02.1992 GB
Titre
(EN) Use of muramyl peptide for the treatment of toxicity
Abrégé
(EN)
Muramyl peptide compounds are useful in the treatment of toxicity, particularly when this condition results from alcohol, hypnotics or sedatives, anaesthetics, opioids or drug abuse generally. The muramyl peptide compound may be of either of general formulae (I) and (II). Preferred compounds include prototype MDP, muroctasin, MTP-PE, murabutide, t-MDP, N-acetyl-glucosaminyl-N-acetyl-muramyl-L-alanyl-D-isoglutamine (GMDP) and N-acetyl-glucosaminyl-N-acetyl-muramyl-L-alanyl-D-glutamic acid (GMDP-A).

Également publié en tant que